<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60424">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01951235</url>
  </required_header>
  <id_info>
    <org_study_id>PXL008-008</org_study_id>
    <secondary_id>2012-004045-33</secondary_id>
    <nct_id>NCT01951235</nct_id>
  </id_info>
  <brief_title>A Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 Diabetes</brief_title>
  <official_title>A Dose-ranging, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 Diabetes Mellitus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poxel SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poxel SA</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the efficacy and safety/tolerability of 4 doses of Imeglimin versus
      placebo. The study will be performed in subjects with type 2 diabetes either naive of
      treatment or previously treated with an oral monotherapy excluding thiazolidinedione.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>Baseline and week 24</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety will be assessed by the incidence of adverse events (AEs), physical examination, relevant changes on laboratory tests, vital signs, and 12-lead electrocardiograms (ECG)</measure>
    <time_frame>Baseline to week 24</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Imeglimin (Dose 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Imeglimin (Dose 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Imeglimin (Dose 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Imeglimin (Dose 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imeglimin</intervention_name>
    <arm_group_label>Imeglimin (Dose 1)</arm_group_label>
    <arm_group_label>Imeglimin (Dose 2)</arm_group_label>
    <arm_group_label>Imeglimin (Dose 3)</arm_group_label>
    <arm_group_label>Imeglimin (Dose 4)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject has given written informed consent

          2. Male and female type 2 diabetic subjects, either naïve of antidiabetic agents or
             treated with an oral anti-diabetic monotherapy.

          3. Body mass index (BMI) : ≥ 24 to ≤ 40 kg/m²

          4. HbA1c criteria: ≥ 7% and ≤ 9.5%

          5. Creatinine clearance ≥ 50 mL/[min*1.73 m2] at Screening Visit

          6. Effective contraception for women of child bearing potential

        Exclusion Criteria:

          1. Any disease which in the investigator's opinion would exclude the subject from the
             study

          2. Acute cardiovascular event within 3 months before randomization

          3. Uncontrolled high blood pressure

          4. Impairment of hepatic function

          5. History of drug-induced Torsades de Pointes or a marked baseline prolongation of the
             QTc interval

          6. Pregnancy or lactation

          7. Use of any non-permitted medication

          8. Positive screen for viral hepatitis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valdis Pirags, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>P. Stradins Clinical University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pascale Fouqueray, MD</last_name>
    <phone>33-6-9801-7103</phone>
    <email>pascale.fouqueray@poxelpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pauls Stradins Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valdis Pirags</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Latvia</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 23, 2013</lastchanged_date>
  <firstreceived_date>September 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
